Limits...
Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus

CT (left), 18F-Alfatide II PET (middle), and 18F-FDG PET (right) of a patient (no. 5) with bladder cancer for 9 years and newly diagnosed with gastric cancer. A lesion in sinuses ventriculi with high FDG uptake was confirmed as adenocarcinoma by biopsy. Multiple metastatic bone lesions were confirmed either as osteolytic (A), osteoblastic (B) or mixed (C) by CT. These lesions showed low or no uptake on 18F-FDG PET and accumulation of 18F-Alfatide II with various intensities.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508500&req=5

Figure 2: CT (left), 18F-Alfatide II PET (middle), and 18F-FDG PET (right) of a patient (no. 5) with bladder cancer for 9 years and newly diagnosed with gastric cancer. A lesion in sinuses ventriculi with high FDG uptake was confirmed as adenocarcinoma by biopsy. Multiple metastatic bone lesions were confirmed either as osteolytic (A), osteoblastic (B) or mixed (C) by CT. These lesions showed low or no uptake on 18F-FDG PET and accumulation of 18F-Alfatide II with various intensities.

Mentions: Based on the image characteristics on CT scans, these bone metastatic lesion were further divided into four categories including the osteolytic, osteoblastic, mixed and bone marrow. Both 18F-Alfatide II and 18F-FDG showed uptake in these lesions with varied intensity. In some cases, 18F-Alfatide II showed higher local accumulation than 18F-FDG, especially in cases of bone marrow metastases (Figure 2 and Figure 3). For all 126 lesions, 18F-Alfatide II PET showed higher positive rate than 18F-FDG PET (92% vs. 77%, Table 3). Especially, all osteolytic and mixed bone metastases were detected by 18F-Alfatide II PET with a sensitivity rate of 100%. 18F-Alfatide II PET was also very sensitive in detection of bone marrow lesions with a sensitivity of 98%, which is significantly higher than 18F-FDG PET (77%). 18F-Alfatide II PET was not so sensitive in detection of osteoblastic lesions but still with a significantly higher detection rate than 18F-FDG PET (70% vs. 53%).


Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

CT (left), 18F-Alfatide II PET (middle), and 18F-FDG PET (right) of a patient (no. 5) with bladder cancer for 9 years and newly diagnosed with gastric cancer. A lesion in sinuses ventriculi with high FDG uptake was confirmed as adenocarcinoma by biopsy. Multiple metastatic bone lesions were confirmed either as osteolytic (A), osteoblastic (B) or mixed (C) by CT. These lesions showed low or no uptake on 18F-FDG PET and accumulation of 18F-Alfatide II with various intensities.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508500&req=5

Figure 2: CT (left), 18F-Alfatide II PET (middle), and 18F-FDG PET (right) of a patient (no. 5) with bladder cancer for 9 years and newly diagnosed with gastric cancer. A lesion in sinuses ventriculi with high FDG uptake was confirmed as adenocarcinoma by biopsy. Multiple metastatic bone lesions were confirmed either as osteolytic (A), osteoblastic (B) or mixed (C) by CT. These lesions showed low or no uptake on 18F-FDG PET and accumulation of 18F-Alfatide II with various intensities.
Mentions: Based on the image characteristics on CT scans, these bone metastatic lesion were further divided into four categories including the osteolytic, osteoblastic, mixed and bone marrow. Both 18F-Alfatide II and 18F-FDG showed uptake in these lesions with varied intensity. In some cases, 18F-Alfatide II showed higher local accumulation than 18F-FDG, especially in cases of bone marrow metastases (Figure 2 and Figure 3). For all 126 lesions, 18F-Alfatide II PET showed higher positive rate than 18F-FDG PET (92% vs. 77%, Table 3). Especially, all osteolytic and mixed bone metastases were detected by 18F-Alfatide II PET with a sensitivity rate of 100%. 18F-Alfatide II PET was also very sensitive in detection of bone marrow lesions with a sensitivity of 98%, which is significantly higher than 18F-FDG PET (77%). 18F-Alfatide II PET was not so sensitive in detection of osteoblastic lesions but still with a significantly higher detection rate than 18F-FDG PET (70% vs. 53%).

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus